Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 5, 2026Cancer Research

Inhibition of STAT3 Axis Induces Antitumor Responses in Pancreatic and Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

RARasaq AkinsolaMOMonday O. OgeseLHLihong Huo

Discussion

Loading...

Member takes

Overview

Researchers demonstrate the inhibition of the STAT3 axis reduces tumor growth in pancreatic and breast cancer, suggesting a potential therapeutic pathway.

Key Points

  • The study investigates how inhibiting the STAT3 pathway affects tumor progression in pancreatic and breast cancer.
  • Used mutant KrasG12D mice and human cancer-associated fibroblasts (CAFs) and tumor cells for analysis.
  • Administered small molecule inhibitors H182 and H279 to assess impact on STAT3 activity.
  • Conducted in vitro assays for cell viability, migration, and apoptosis, and evaluated tumors in xenograft models.
  • Inhibition of STAT3 led to decreased production of pro-inflammatory cytokines and chemokines.
  • Treatment with H182 and H279 resulted in cell cycle arrest and increased apoptosis in cancer cells.
  • H182 prevented acinar cell de-differentiation and reduced tumor growth in PDAC xenografts.

Cite This Study

Akinsola et al. (2026) studied this question.

synapsesocial.com/papers/69d1fdbfa79560c99a0a3fefhttps://doi.org/10.1158/1538-7445.am2026-4563
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract A103: Targeting STAT3 in cancer-associated fibroblasts reprograms the stroma and enhances CD8+ T cell-mediated immunity in PDAC2025
  2. 2Abstract 663: Irreversible covalent azetidine-based small molecule inhibitors of Stat3 activity block growth of human pancreatic tumors2024
  3. 3Abstract B041: Fibroblast STAT3 Signaling in Pancreatic Cancer: Implications for Immunotherapy and Tumor Microenvironment Modulation2024
  4. 4Abstract B013: Hepatocyte STAT3 signaling drives response to immunotherapy in pancreatic cancer2025
  5. 5Abstract C011: Targeting STAT3 overcomes PDAC resistance to EGFR/RAF1 inhibition leading to complete and durable tumor regression2024